Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis

Archives of Ophthalmology

Volumn 123, Issue 5, 2005, Pages 634-641

  Murphy, Conor C ^a   Greiner, Kathrin ^b   Plskova, Jarka ^b   Duncan, Linda ^b   Frost, N Andrew ^c   Forrester, John V ^b   Dick, Andrew D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c TORBAY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; CARDIOVASCULAR SYMPTOM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EYE INFLAMMATION; FATIGUE; FEMALE; FLOW CYTOMETRY; GINGIVA HYPERPLASIA; GINGIVA HYPERTROPHY; HEADACHE; HEART PALPITATION; HIRSUTISM; HUMAN; HYPOMAGNESEMIA; INSOMNIA; MALE; MEAN ARTERIAL PRESSURE; MUSCLE CRAMP; NAUSEA; OPHTHALMOSCOPY; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THORAX PAIN; THRUSH; TREMOR; URINARY DYSFUNCTION; UVEITIS; VISUAL ACUITY; BLOOD; BLOOD PRESSURE; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGY; IMMUNOPHENOTYPING; INTERMEDIATE UVEITIS; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BLOOD PRESSURE; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CYCLOSPORINE; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TACROLIMUS; TREATMENT OUTCOME; UVEITIS, INTERMEDIATE; UVEITIS, POSTERIOR; VISUAL ACUITY;

EID: 18444362109     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.5.634     Document Type: Article

References (30)

1. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983;96:275-282.
2. Towler HM, Cliffe AM, Whiting PH, Forrester JV. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye. 1989;3:282-287.
3. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103:365-374.
4. Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol. 1997;81:1107-1112.
5. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46:746-794.
6. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115:763-769.
7. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723-728.
8. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm. 1998;6:101-109.
9. Jensik SC; FK 506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc. 1998;30:1216-1218.
10. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360:1119-1125.
11. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation. 1994;57:848-851.
12. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol. 2001;12:368-373.
13. Textor SC, Wiesner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993;55:1332-1339.
14. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc. 1998;30:1240-1242.
15. Claesson K, Mayer AD, Squifflet JP, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc. 1998;30:1292-1294.
16. Benezra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P. Uveitis Scoring System. Berlin, Germany: Springer-Verlag; 1991.
17. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1: Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796-1806.
18. Jenkinson C, Layte R, Wright L, Coulter A. The UK-SF-36: An Analysis and Interpretation Manual. Oxford, England: Joshua Horgan Print Partnership; 1996.
19. Frost NA, Sparrow JM, Durant JS, Donovan JL, Peters TJ, Brookes ST. Development of a questionnaire for measurement of vision-related quality of life. Ophthalmic Epidemiol. 1998;5:185-210.
20. Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170-176.
21. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18:336-345.
22. McCune TR, Thacker LR II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation. 1998;65:87-92.
23. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13:2962-2968.
24. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989;262:53-56.
25. Murphy CC, Greiner K, Plskova J, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory non-infectious posterior uveitis. Arch Ophthalmol. 2004;122:845-851.
26. Dees C, Arnold JJ, Forrester JV, Dick AD. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998;116:1456-1461.
27. Rosenbaum JT, Deodhar A, Suhler EB, Smith JR. How do you know? Br J Ophthalmol. 2004;88:980-981.
28. Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci. 2001;42:1285-1292.
29. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
30. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-296.